Clinical Trials Browser

Phase 1 × spartalizumab × Plasma cell × Clear all

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase 1 Completed

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell